

Remarks

This Amendment is submitted in response to the office action mailed November 3, 2004, in connection with the above-identified application (hereinafter, the "Office Action"). The Office Action provided a three-month shortened statutory period in which to respond, ending on February 3, 2005. Accordingly, this Amendment is timely submitted.

Claims 1, 3, and 5 through 13 are currently pending. Applicants respectfully request the entry of the amendments to Claims 1 and 3. Applicants respectfully submit that the amendments to the pending claims do not introduce any new matter.

Amendments to the Claims

Applicants respectfully request the amendment to Claim 1 be entered to correct the prior typographical errors. Applicants have replaced "R3" and "R4" with "R₃" and "R₄" respectively in the third sentence because the text as previously written had been missing subscripts. Furthermore, a semicolon was added within the third sentence.

Applicants respectfully also request the entry of the amendment to Claim 3. This amendment corrects the dependency of Claim 3 on Claim 1.


Obvious-Type Double Patenting

Claims 1, 4 and 6 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 10-12 of U.S. Patent No. 6,596,877 to Shieh et al. Applicants submit herewith a terminal disclaimer referencing U.S. Patent No. 6,596,877. Thus, Applicants respectfully submit that this rejection has been overcome.

Applicants respectfully submit that the present application is in condition for allowance. If a telephone interview would be of assistance in advancing the prosecution of this application, Applicants' undersigned attorney invites the Examiner to telephone him at the telephone number provided below.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7877


John W. Kung
Attorney for Applicants
Reg. No. 44,199

Date: 12-09-2004